Augmentation of NK cell-mediated anti-cancer activity by dietary BITC
Augmentation of NK cell-mediated anti-cancer activity by dietary BITC
批准号:
7701342
负责人:
Per H. Basse
金额:
$16.67万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-17 至 2011-06-30
关键词:
AnimalsCancerousCell physiologyCellsCellular biologyClinicalClinical TrialsDevelopmentDietary ComponentDietary intakeDisease modelDrug or chemical Tissue DistributionEpidemiologic StudiesGeneticGoalsHumanImmunityIn VitroIntakeInterferon Type IIKineticsLyticMalignant NeoplasmsMalignant neoplasm of prostateMediatingModelingMusNatural Killer CellsNeoplasm MetastasisOutcome StudyPhenotypePrimary NeoplasmProductionResearch DesignRiskRoleTestingTumor Necrosis Factor-alphaVirusbasebenzyl isothiocyanatecancer chemopreventioncancer preventioncarcinogenesiscruciferous vegetableexperiencein vitro activityin vivoinsightkillingsneoplastic cellnovelpre-clinicalprostate cancer preventionprostate carcinogenesispublic health relevancestemtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Natural killer (NK) cells are able to recognize and kill aberrant (i.e., cancerous and virus-infected) cells without priming and independently of the antigenic presentation/composition of the target. NK cells have been shown to protect against development of cancer. Accordingly, identification and pre-clinical/clinical development of agents that are relatively safe but can boost NK cell function are highly desirable with immense translational application for chemoprevention of cancers. This project seeks to test a novel hypothesis that prostate cancer prevention by benzyl isothiocyanate (BITC), a constituent of many edible cruciferous vegetables, is at least in part mediated by augmentation of NK cell function. This hypothesis stems from our novel preliminary unpublished results showing BITC-mediated augmentation of NK cell lytic activity in vitro at pharmacologically relevant concentrations. In addition, the BITC-mediated augmentation of NK cell lytic activity correlates with increased production of interferon gamma (IFN3) and tumor necrosis factor-alpha (TNF1) by the NK cells. Despite these encouraging results, the in vivo significance of these in vitro observations is unclear. Likewise, the mechanism by which BITC augments NK cell activity remains elusive. The overall objective of this application is to systematically probe into these questions using prostate cancer as a disease model. The rationale for focusing on prostate cancer is based on the following considerations: (a) epidemiological studies have indicated an inverse correlation between dietary intake of cruciferous vegetables and the risk of prostate cancer, and (b) a very recent study has provided important genetic evidence for surveillance of primary tumors by NK cells in the TRAMP model of prostate cancer. The specific aims of this proposal are to (1) determine the concentration effect relationship for dietary BITC administration on tumoricidal activity of NK cells in vivo and to gain insight into the mechanism of this effect, and (2) determine whether dietary BITC- mediated boost of NK cell activity leads to suppression of prostate carcinogenesis and metastasis in TRAMP mice in vivo. Positive outcome of these studies will form a firm basis for clinical trials to determine BITC-mediated augmentation of NK cell activity and prostate carcinogenesis in humans. ) PUBLIC HEALTH RELEVANCE: We have found that dietary benzyl-isothiocyanate (BITC) is able to augment host NK cell function. In this project, we will investigate the in vivo aspects of BITC intake on the tumoricidal capacity of the host's NK cells. We will first determine the concentration effect relationship for dietary BITC administration on the tumoricidal activity of NK cells in vivo and we will determine the mechanism behind this effect. We will then determine whether the dietary BITC-mediated boost of NK cell activity leads to suppression of carcinogenesis and metastasis in the TRAMP model of prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INITIATING THE ADAPTIVE IMMUNE RESPONSE TO CANCER
-
批准号:7128908
-
项目类别:
-
资助金额:$16.9万
-
财政年份:2005
-
负责人:Per H. Basse
-
依托单位:
Cytokine Delivery By Tumor-Seeking Lymphocytes
-
批准号:6865438
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2004
-
负责人:Per H. Basse
-
依托单位:
Cytokine Delivery By Tumor-Seeking Lymphocytes
-
批准号:6709079
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2004
-
负责人:Per H. Basse
-
依托单位:
Cytokine Delivery By Tumor-Seeking Lymphocytes
-
批准号:7010096
-
项目类别:
-
资助金额:$22.25万
-
财政年份:2004
-
负责人:Per H. Basse
-
依托单位:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
-
批准号:6621281
-
项目类别:
-
资助金额:$24.82万
-
财政年份:2002
-
负责人:Per H. Basse
-
依托单位:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
-
批准号:6431298
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2002
-
负责人:Per H. Basse
-
依托单位:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
-
批准号:6687272
-
项目类别:
-
资助金额:$24.59万
-
财政年份:2002
-
负责人:Per H. Basse
-
依托单位:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
-
批准号:6323292
-
项目类别:
-
资助金额:$17.92万
-
财政年份:2000
-
负责人:Per H. Basse
-
依托单位:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
-
批准号:6203349
-
项目类别:
-
资助金额:$17.92万
-
财政年份:1999
-
负责人:Per H. Basse
-
依托单位:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
-
批准号:6103168
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1998
-
负责人:Per H. Basse
-
依托单位:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
-
批准号:6237646
-
项目类别:
-
资助金额:$12.7万
-
财政年份:1997
-
负责人:Per H. Basse
-
依托单位:
IMMUNOTHERAPY OF EARLY, LATE, AND DORMANT METASTASES
-
批准号:2109202
-
项目类别:
-
资助金额:$10.15万
-
财政年份:1995
-
负责人:Per H. Basse
-
依托单位:
IMMUNOTHERAPY OF EARLY, LATE, AND DORMANT METASTASES
-
批准号:2633890
-
项目类别:
-
资助金额:$10.98万
-
财政年份:1995
-
负责人:Per H. Basse
-
依托单位:
IMMUNOTHERAPY OF EARLY, LATE, AND DORMANT METASTASES
-
批准号:2008707
-
项目类别:
-
资助金额:$10.55万
-
财政年份:1995
-
负责人:Per H. Basse
-
依托单位:
IMMUNOTHERAPY OF EARLY, LATE, AND DORMANT METASTASES
-
批准号:2109201
-
项目类别:
-
资助金额:$9.55万
-
财政年份:1995
-
负责人:Per H. Basse
-
依托单位:
IMMUNOTHERAPY OF EARLY, LATE, AND DORMANT METASTASES
-
批准号:2856381
-
项目类别:
-
资助金额:$11.41万
-
财政年份:1995
-
负责人:Per H. Basse
-
依托单位:
IN VIVO MIGRATION OF NK AND A-LAK CELLS
-
批准号:3021429
-
项目类别:
-
资助金额:$2.65万
-
财政年份:1989
-
负责人:Per H. Basse
-
依托单位:
IN VIVO MIGRATION OF NK AND A-LAK CELLS
-
批准号:3021428
-
项目类别:
-
资助金额:$0.85万
-
财政年份:1989
-
负责人:Per H. Basse
-
依托单位:
INITIATING THE ADAPTIVE IMMUNE RESPONSE TO CANCER
-
批准号:7560575
-
项目类别:
-
资助金额:$34.43万
-
财政年份:--
-
负责人:Per H. Basse
-
依托单位:
INITIATING THE ADAPTIVE IMMUNE RESPONSE TO CANCER
-
批准号:7678612
-
项目类别:
-
资助金额:$31.52万
-
财政年份:--
-
负责人:Per H. Basse
-
依托单位:
海外基金